We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cleveland BioLabs Announces New US Patent Allowances for CBLB502 and CBLB612
News

Cleveland BioLabs Announces New US Patent Allowances for CBLB502 and CBLB612

Cleveland BioLabs Announces New US Patent Allowances for CBLB502 and CBLB612
News

Cleveland BioLabs Announces New US Patent Allowances for CBLB502 and CBLB612

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cleveland BioLabs Announces New US Patent Allowances for CBLB502 and CBLB612"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioLabs, Inc. has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its Protectan CBLB502 U.S. Patent Application Number 11/722,682, titled "Flagellin Related Polypeptides and Uses Thereof." Allowed claims cover composition of matter and use of CBLB502 for protecting a mammal from radiation.

The U.S. Patent and Trademark Office also issued a Notice of Allowance for the Company's Protectan CBLB612 patent application number 11/917,494, titled "Methods of Protecting against Apoptosis using Lipopeptides."

Allowed claims cover the various properties of Protectan CBLB612 and related compounds, including composition of matter and methods of use for protecting against apoptosis.

Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, stated, "We are pleased to see the patent portfolio protecting our compounds and technology continue to expand in the US and around the world. These patents validate our unique approach to protection of healthy tissues from the impact of radiation and other acute stresses."

The Company also announced receipt of a Notice of Allowance from the New Zealand patent authority for a patent covering the various properties of Protectan CBLB612 and related compounds, including composition of matter and methods of use for protecting against apoptosis, as well as issuance of a patent for Protectan CBLB612 from the patent authority of South Africa, titled "Method for Increasing and Mobilizing Stem Cells."

Advertisement